Abstract
Direct-acting oral anticoagulants (DOACs) are licensed for the prevention of thromboembolism in non-valvular atrial fibrillation, amongst other indications. Prescribers use information derived from the summary of product characteristics which is based on the key trials supporting the DOAC's market authorisation. However, prescribers may not be aware of the limitations within these trials regarding underrepresentation of patient populations commonly encountered in clinical practice and how this may adversely impact them. This review highlights the gaps in the licensing evidence using four clinical vignettes that explore prescribing challenges in older adults, female patients, patients with obesity and patients from non-Europid ethnic backgrounds.
| Original language | English |
|---|---|
| Pages (from-to) | 4724-4731 |
| Journal | British Journal of Clinical Pharmacology |
| Volume | 88 |
| Issue number | 11 |
| Early online date | 30 Jun 2022 |
| DOIs | |
| Publication status | E-pub ahead of print - 30 Jun 2022 |
Keywords
- anticoagularnts
- cardiovascular pharmacology
- drug information
- drug regulation
- medication safety
Access to Document
- AdeyeyeE2022Prescribing
This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.